Cardiovascular disease (CVD) is the leading cause of death in the United States and aging is a major risk factor for CVD development. One of the major age-related arterial phenotypes thought to be responsible for the development of CVD in older adults is endothelial dysfunction. Endothelial function is modulated by traditional CVD risk factors in young adults, but advancing age is independently associated with the development of vascular endothelial dysfunction. This endothelial dysfunction results from a reduction in nitric oxide bioavailability downstream of endothelial oxidative stress and inflammation that can be further modulated by traditional CVD risk factors in older adults. Greater endothelial oxidative stress with aging is a result of augmented production from the intracellular enzymes NADPH oxidase and uncoupled eNOS, as well as from mitochondrial respiration in the absence of appropriate increases in antioxidant defenses as regulated by relevant transcription factors, such as FOXO. Interestingly, it appears that NFkB, a critical inflammatory transcription factor, is sensitive to this age-related endothelial redox change and its activation induces transcription of pro-inflammatory cytokines that can further suppress endothelial function, thus creating a vicious feed-forward cycle. This review will discuss the two macro-mechanistic processes, oxidative stress and inflammation, that contribute to endothelial dysfunction with advancing age as well as the cellular and molecular events that lead to the vicious cycle of inflammation and oxidative stress in the aged endothelium. Other potential mediators of this pro-inflammatory endothelial phenotype are increases in immune or senescent cells in the vasculature. Of note, genomic instability, telomere dysfunction or DNA damage have been shown to trigger cell senescence via the p53/p21 pathway that results in increased inflammatory signaling in arteries from older adults. This review will discuss the current state of knowledge regarding the emerging concepts of senescence and genomic instability as mechanisms underlying oxidative stress and inflammation in the aged endothelium. Lastly, energy sensitive/ stress resistance pathways (SIRT-1, AMPK, mTOR) are altered in endothelial cells and/or arteries with aging and these pathways may modulate endothelial function via key oxidative stress and Corresponding Author: Anthony J. Donato, Ph.D., Department of Internal Medicine, Division of Geriatrics, University of Utah, 500 foothill Dr., Salt Lake City, UT 84148, USA, Phone: (801) 582-1565 ext. 4237, tony.donato@utah.edu, http://www.tvplab.utah.edu.
endothelium is in a tightly regulated state of balance between pro-and anti-oxidants, vasodilators and vasoconstrictors, pro-and anti-inflammatory molecules, and pro-and antithrombotic signals. A diseased or dysfunctional endothelium that has lost its tightly regulated balance and displays pro-oxidant, vasoconstrictor, pro-inflammatory and prothrombotic properties. One hallmark of vascular endothelial dysfunction is impaired endothelial dependent dilation (EDD), which is predictive of future CVD events [3, 17] . Indeed, the Framingham Heart Study has recently demonstrated that increased age is the strongest independent correlate of EDD [18] . Therefore, it is of great clinical significance that we obtain a better understanding of the mechanisms underlying age-related decreases in endothelial function and to test the efficacy of interventions that may restore endothelial function in middle-aged and older adults.
Goal of the Review
The first goal of this review will be to introduce the two macro-mechanistic processes, oxidative stress and inflammation, that contribute to endothelial dysfunction in healthy older adults and rodent models. Next, we will discuss the cellular and molecular events that lead to the vicious cycle of inflammation and oxidative stress in the aged endothelium. Then, we will discuss the emerging concepts of senescence and genomic instability as it relates to the aforementioned processes. Lastly, we explore how "energy sensing" longevity pathways that appear to modulate endothelial function with advancing age. In this review, we will focus first on in vivo or ex vivo studies that directly examined endothelial cells. However, a major obstacle to our understanding of the events that lead to endothelial dysfunction with advancing age is access to pure primary endothelial cells from humans or rodent models. Next, we will consider studies utilizing whole artery homogenates with the understanding that protein expression in whole arteries is strongly biased toward the smooth muscle cell component rather than the endothelium. Lastly, this review will explore the mechanisms of endothelium dysfunction defined as reductions in EDD assessed by the response to pharmacological or physiological stimuli. Our focus on EDD is because a majority of studies that perform mechanistic studies utilize this marker. It is not to say measures of angiogenesis, permeability, fibrinolysis or other markers of endothelial function are not as important; indeed these are critical functions which are vastly understudied, but at the present time, the mechanisms leading to impairments in these functions in aged endothelial cells or their direct relation to CVD development are not clearly understood.
of endothelial dysfunction as assessed by EDD (as reviewed in depth by Seals et al. [6] ). Interestingly most of these factors have been shown to modulate endothelial function via oxidative stress or inflammation, as described in detail below. Lastly, it is known that with advancing age post prandial clearance of elevated glucose and lipids decreases significantly even in healthy adults [39, 40] . Furthermore, this post prandial state is associated with acute endothelial dysfunction in young and middle aged adults [41, 42] . Thus, it is a tenable hypothesis that this post prandial state underlies the vascular aging phenotype since endothelial culture studies suggest that physiological elevations in glucose and lipids induce oxidative stress and inflammation and also negatively alter "energy sensitive" pathways [43] [44] [45] . Due to the lack of appropriate fasting time to resolve the acute metabolic insults, these alterations in apparently normal healthy middle aged and older adults may "set the table" for sustained endothelial dysfunction mediated by chronic vascular endothelial oxidative stress and inflammation. This viable hypothesis needs to be empirically tested, but would be consistent with the existing associative data.
3a. Aging, Nitric Oxide (NO) Bioavailability and Endothelial Function
In the vascular endothelium, L-arginine and the cofactors; BH4 and FADH, are necessary for the production of NO by the enzyme endothelial NO synthase (eNOS) [46] . NO is one of the most important vasodilatory and anti-atherosclerotic molecules produced by the endothelium [46] [47] [48] . The major mechanism involved in the age-related reduction in EDD is reduced vascular NO bioavailability [49] . While initially thought to be the result of reduced expression of eNOS [50] [51] [52] , evidence from endothelial cells collected from human and animal arteries demonstrates that eNOS protein expression cannot explain the reduction in NO bioavailability with advancing age [19, [53] [54] [55] . Rather, it appears that alterations in eNOS activation status, substrate/cofactor availability and/or inactivation of NO underlie the age-related reduction in NO bioavailability and impairments in EDD. Recent evidence also suggests that prostanoid vasodilators, such as prostacyclin, are diminished with advanced age [56, 57] and may explain some of the reductions in vasodilation. Furthermore, it is appreciated that reductions in NO promote enhanced vasoconstriction mediated by endothelial derived ET-1 [58, 59] . It has been shown that aging results in elevated expression of ET-1 and cyclooxgenase (producer of vasoconstrictor prostaglandins) [19, 58, 60, 61] and this elevation suppresses endothelial vasodilation in older adults and rodent models [19, 62] . Next we will delineate the two macro mechanistic processes which directly lead to suppression of endothelial function in older adults.
3b. Aging, Oxidative Stress and Endothelial Dysfunction
In humans, sedentary aging is considered a state of chronic, systemic "oxidative stress" [63] based primarily on observations of age-related elevations of plasma oxidative stress markers [21, 64, 65] . A key mechanism underlying age-associated reductions in EDD and NO bioavailability is the development of vascular oxidative stress [21, 49, [66] [67] [68] [69] . Oxidative stress can be defined as a state in which the bioavailability of reactive oxygen species (ROS) is increased relative to antioxidant defenses [70] [71] [72] . Superoxide anion (O 2 − ) is a ROS produced by oxidant enzyme systems (NADPH oxidase-p67 phox, xanthine oxidase, cytochrome P450 2C9, uncoupled eNOS) [70, 71, 73, 74] that can inactivate NO [71, 75] . Interestingly, O 2 − can also be produced in abundance in the mitochondria at complex 1 and [112, 113] and humans [114] . This age-associated pro-inflammatory arterial phenotype is downstream of increased nuclear factor κB (NFκB) activity. NFκB is a transcription factor that resides in the cytoplasm through its interaction with the inhibitory protein, I kappa B-alpha (IκB-α) [115, 116] . In response to inflammatory stimuli [116] or ROS [117] [118] [119] , I kappa B kinase beta (IKKβ) is activated and subsequently phosphorylates IκB-α, releasing its inhibition and allowing NFκB to translocate into the nucleus where it can activate gene transcription of pro-inflammatory cytokines [120] . Supporting the critical role of NFκB in age-related inflammation dependent endothelial dysfunction is evidence that pharmacological inhibition of NFκB signaling significantly reduces cytokines and enhances EDD in old mice and humans [113, 121, 122] .
This pro-inflammatory arterial phenotype has been demonstrated in the vascular endothelial cells of older healthy humans [22, 91] and underlies endothelial dysfunction in older humans and mice [113, 121] . Evidence for a direct role of inflammation in endothelial dysfunction is provided by studies in which exogenous administration of pro-inflammatory cytokines was shown to induce endothelial dysfunction or endothelial activation in primary endothelial cells or isolated arteries [123] [124] [125] . Such an inflammation-mediated endothelial dysfunction has also been observed in vivo in carotid arteries of aged rats [52] and in adipose tissue arteries of mice with diet-induced obesity [125] , with the dysfunction occurring downstream of elevated TNF-α. In vivo arterial TNF-α may be produced locally by vascular cells [52, 112] or by immune cells infiltrating the adventitia of the large arteries [112] . TNF-α associated pro-inflammatory signaling may occur both up-and down-stream of elevated NFκB activity which itself underlies vascular dysfunction, at least in part, via increases in oxidative stress [52, 112, 113] .
In addition to exacerbating inflammation downstream of NFκB transcription of proinflammatory cytokines, inflammatory signaling also stimulates O 2 − production and oxidative stress (and vice versa) through a number of mechanisms. These include increased NFκB mediated transcription of redox-sensitive genes like those encoding subunits of NADPH oxidase [126] [127] [128] that increase ROS bioactivity and further activation of IKK-NFκB signaling. Thus, NFκB lies at the center of a vicious cycle that can exacerbate oxidative stress and inflammation ( Figure 2 ). Interestingly, endothelial NFκB can impact the healthspan/lifespan beyond its effects on vascular function per se. Indeed, inhibition of endothelial NFκB signaling protects against not only age-associated vascular senescence and oxidative stress, but also protects against diet-and age-associated insulin resistance and increases lifespan in a mouse model expressing a dominant negative IKK in the endothelium [129] .
In addition to NFκB signaling, there are a number of other inflammation-sensitive pathways that may also be involved in age-associated vascular dysfunction. Inflammatory and growth factor stimuli destabilize the vascular endothelium [130] [131] [132] via activation of the small GTPase, ADP-ribosylation factor 6 (ARF6), its activator ARF nucleotide binding site opener (ARNO) and the downstream GTPase, Rac [132] . ARF6-ARNO-Rac act to reduce endothelial cell-cell interactions promoting vascular permeability, leukocyte adhesion and angiogenesis [132] [133] [134] . Dysregulation of this inflammation-sensitive pathway can lead to disruption of normal endothelial barrier function, vascular leak, tissue disruption and pathological angiogenesis in retinal vascular disease [132, 134] . However, the impact of aging on this pathway and its role in vascular aging are unknown. Similarly, inflammatory signaling activates the Notch pathway to inhibit cell growth and promote hyper permeability and cell senescence (the implications of which will be discussed later in this review) [135, 136] . Interestingly, Notch signaling is enhanced in atherosclerotic regions of aortas from mice and humans and is activated in endothelial cells of older adults [135] . Notch activity is also increased in models of accelerated aging in response to progerin expression, a mutant "prelamin A" protein [137, 138] . Moreover, expression of the progerin protein is elevated in vascular tissues and cells from otherwise healthy aged humans [139, 140] , suggesting that augmented Notch signaling may underlie at least some of the effects of vascular aging [141] . Thus, in addition to NFκB, other inflammation-sensitive pathways also have the potential to play a role in vascular dysfunction, e.g. impaired endothelial barrier function/vascular hyperpermeability [26, 31, 142, 143] and increases in cell senescence, all of which are associated with advancing age.
Cellular Senescence and Genomic Instability 4a. Cellular Senescence in Endothelial Aging
Cellular senescence, or permanent cell cycle arrest, is considered cellular aging, as it occurs in vitro after a certain number of cell cycles and in response to excessive intracellular and extracellular stressors [144, 145] . Senescence primarily occurs in the G0/G1 phase of the cell cycle and is a vital tumor suppressive mechanism that prevents passing damaged DNA to daughter cells or potential neoplastic transformation of damaged cells [144, 145] . Since being first described by Leonard Hayflick as an in vitro phenomenon in human fibroblasts, the potential role of senescence in in vivo aging and disease has been difficult to assess and somewhat controversial [146] . However, recent studies have shown that senescent cells accumulate in normal arterial tissue over the lifespan of humans [147, 148] . Likewise, the accumulation of senescent cells has been reported in diseased tissues, such as atherosclerotic plaques [149] and abdominal aortic aneurysms [150] . Baker et al. showed that clearance of senescent cells reversed aged and diseased phenotypes in a mouse model of accelerated aging [151] . This important study strongly suggested that there were phenotypic properties of senescent cells that were problematic to tissues, and potentially contribute to aging and chronic disease.
There are several causes of cellular senescence in mammalian cells, including excessive mitogenic signals [152] , increases in extracellular or intracellular stressors like oxidative stress [153] , chromatin disruptions [154] , and DNA damage [155] . Senescence is induced by the two major tumor suppressor pathways, known as the p53 and p16/pRB pathways [156] . The p53 pathway depends on activation of the transcription factor p53 by a number of different signaling cascades [156] . One of the most important of these is the DNA damage response pathway [155, 157] . The p16/pRB pathway involves cyclin-dependent kinase inhibitors 2A (p16)-mediated inhibition of retinoblastoma-like protein 1 (pRB) [158] . The preference toward one pathway versus another appears to be cell type-specific [156, 159] , with variation across species [160] . For example, telomere dysfunction can lead to activation of the p53 or p16/pRB pathway in human cells, but will only trigger the p53 pathway in rodent cells [160] . The general consensus seems to be that senescence via the p53 pathway is activated primarily by DNA damage and telomere dysfunction, while the p16/pRB pathway is linked primarily to mitogenic stress, chromatin disruptions, or general cellular stress [156, 159, 161] .
In vitro senescent cells are characterized by a pro-inflammatory, pro-oxidative senescenceassociated phenotype (SASP) [144] . The release of inflammatory mediators and ROS production likely reinforces cell cycle arrest in an autocrine fashion and activates immune cell surveillance of senescent cells [144, 162] . The SASP occurs within a few days of senescence induction in cells and appears to be irreversible due to stable chromatin modifications around clusters of SASP genes [163] [164] [165] . The SASP profile in vascular endothelial cells from humans and rodents has been characterized by in vitro studies using comprehensive arrays of inflammatory cytokines and chemokines [144, [165] [166] [167] [168] [169] . The release of IL-6, IL-1, IL-8, TNF-α, and monocyte chemoattractant protein-1 (MCP-1) has been linked to p53-mediated senescence in human vascular cells in vitro [170, 171] . Interestingly, P16/pRB-induced senescence has not been shown to lead to a SASP in human cells [144, 164] . Additionally, human arterial endothelial cells that had undergone replicative senescence in vitro exhibited elevated levels of H 2 O 2 and O 2 − as well as reductions in NO [172, 173] . This SASP profile is possibly due to mitochondrial uncoupling or alterations in eNOS [172, 174] . Several lines of evidence support a major role for NFκB in the induction and maintenance of the p53-mediated SASP in human and rodent cells [175] [176] [177] . Indeed, inhibition of NFκB allowed cells to escape p53-mediated senescence and reduced oxidative stress in rodents [175, 177] . This alludes to the importance of the SASP in reinforcing p53-mediated senescence and the importance of NFκB in promoting the SASP. Additionally, p53 activation leads to a shift from glycolytic to oxidative phosphorylation energy metabolism [178] , which could result in increased flux through the electron transport chain and ROS release from mitochondria. Taken together endothelial cell senescence could be cause or consequence of the age-related increase in oxidative stress and likely contributes to the spread of vascular inflammation via the SASP, from senescent cells (Figure 3 ). Lastly this chronic inflammation could persist and accumulate, indefinitely in the vasculature until removal of the senescent cells, thus limiting therapeutic options.
4b. Aging, Genomic Instability, Cellular Senescence and Endothelial Dysfunction
Genomic instability, or DNA damage acquired over time, is an important mechanism that may underlie the age-related accumulation of senescent cells reported in arterial tissues [147, 148] . Age-related genomic instability in vascular cells can occur from a variety of genotoxic insults, including oxidative stress [179, 180] and mechanical stress [181] . DNA damage results in temporary cell cycle arrest to allow DNA repair pathways time to repair breaks prior to a cell entering S phase during replication [155] . If damage is persistent or extensive, permanent cell cycle arrest or even apoptosis will ensue [155] . Common forms of DNA damage relevant to aging include single and double strand DNA breaks and DNA adducts. While the age-related accumulation of DNA breaks and DNA adducts have not been shown in human vascular cells, DNA breaks have been shown to occur with advancing age in sperm cells [182] and the mitochondrial DNA of skeletal muscle [183, 184] . Microsatellite instability and loss of heterozygosity, which is thought to be a consequence of DNA breaks, has been linked to pulmonary artery hypertension [185] and atherosclerosis [186] [187] [188] [189] [190] [191] in humans. Interestingly, two recently developed mouse models of disrupted DNA adduct repair (xeroderma pigmentosum D (XPD) ttd and ERCC1 d/− mice) demonstrated age-related impairments in EDD in response to acetylcholine, reduced eNOS expression and activity, and increased p53 expression and ROS content [192] .
Telomere dysfunction is another form of genomic instability that may lead to cellular senescence with advancing age. First described by Harley et al., senescence triggered by replication-dependent telomere dysfunction is often referred to as replicative senescence [193] . Telomeres can be damaged by the genotoxic stressors described above [194, 195] , and in vitro studies in various human cell types have clearly shown that the breakdown of telomere structure, referred to as telomere uncapping, leads to p53 activation and senescence [196, 197] . The only previous study to measure arterial telomere uncapping reported greater uncapping with advancing age, which was linked to p53-mediated senescence [148] .
A vicious cycle of oxidative stress leading to DNA damage or telomere uncapping-mediated p53 activation and subsequent senescence-associated oxidative stress is a simple model of the role of genomic instability in age-related endothelial dysfunction. However, a more integrative model might consider the influence of p53-mediated shifts in energy metabolism on the following [178] energy sensitive pathways: SIRT-1, AMPK and mTOR that are known to influence both aging and endothelial function and that are discussed next.
Energy Sensing Longevity Pathways 5a. SIRT-1, Aging and Endothelial Dysfunction
Sirtuins were originally discovered in a screen for gene silencing factors in yeast and, therefore, given the name Sir2 (silent information regulator 2). Little research was conducted on the Sir2 family until Guarente et al. identified these proteins as critical regulators of longevity [198] [199] [200] . Thereafter, Sir2 and its mammalian homologues, the sirtuin family (SIRT1-7), of NAD+-dependent protein deacetylases and ADPribosyltransferases were quickly identified. In mammals, SIRT1-4 have been implicated in the control of cellular metabolism with SIRT-2, 3 and 4 predominantly expressed in the mitochondria and SIRT-1 expressed in the nucleus, with some cytoplasmic expression [201] [202] [203] . The sirtuin family and specifically SIRT-1 are implicated in a majority of the physiological benefits of caloric restriction [203] [204] [205] . SIRT-1 expression decreases in a multitude of tissues with advancing age [206] [207] [208] . SIRT-1 function is related to deacetylation and thereby modulating activity of nuclear transcription factors, co-regulators and proteins to adapt gene expression in response to the cellular energy state and provide "stress resistance" by reducing pro-inflammatory and oxidative stress pathways [209] . Interestingly, activation of SIRT-1 with the small molecule SRT1720 increases lifespan and preserves glucose tolerance in rodents [210] Taken together these data suggest that SIRT-1 activation may have significant promise for improving endothelial function with aging or CVD.
SIRT-1 has been reported to modulate NO and endothelial function in small and large arteries directly via deacetylation and subsequent activation of eNOS [207, 211] . Our group has demonstrated that SIRT-1 expression and activity decrease with age in the vasculature in both mice and humans [104, 207, 212, 213] , and this is associated with age-related endothelial dysfunction in mice [104, 207] . Interestingly in rodent models, both short and long term caloric restriction can prevent the decline in arterial SIRT-1 and endothelial function [104, 212, 214] . Most of the data related to the vascular endothelium and SIRT-1 activators is restricted to studies utilizing resveratrol, a naturally occurring polyphenol [215] . Unfortunately, resveratrol must be used at high doses to activate SIRT-1 [216] and is known to activate over 15 unique pathways in addition to being a potent antioxidant and phytoestrogen [215, [217] [218] [219] [220] [221] . While these characteristics of resveratrol do not alter its potential therapeutic value, they do generate some difficulty in elucidating its mechanism of action, specifically whether SIRT-1 activation is responsible for its beneficial effects. It has been shown that very high doses of resveratrol (2400 mg/kg of food) improves EDD in isolated arteries from middle-aged animals after 1 year of treatment [222] , although it is unknown by what mechanism(s) this effect was achieved. Subsequently, we have utilized SRT-1720 treatment in old mice and have demonstrated that four weeks of SRT-1720 normalizes SIRT-1 activity and reduces age-related NFκB acetylation, arterial inflammation and oxidative stress [213, 223] . Somewhat surprisingly SRT-1720 improvements in EDD were not mediated by increased NO bioavailabilty in old mice, but rather via augmented COX-2 vasodilators [213, 223] . Therefore, despite strong evidence suggesting a role of reduced SIRT-1 in the age-related reduction in NO bioavailability and endothelial dysfunction, treatment with a SIRT-1 activator improves endothelial function and reduced oxidative stress and inflammation, but does not restore NO. Future studies will be needed using small molecule activators of sirtuins to determine if they can ameliorate age-related CVD pathologies.
5b. AMP-activated protein kinase (AMPK), Aging and Endothelial Dysfunction
AMPK, a highly conserved heterotrimeric serine-threonine kinase, is an important energy sensing signaling protein that integrates energy balance, metabolism and stress resistance [224, 225] . AMPK is activated in response to increases in the AMP:ATP ratio and following physiological stimuli such as shear stress, heat shock, exercise and hypoxia [226] . AMPK is made up of a catalytic α subunit, a structural β subunit and the AMPK binding site containing γ subunit, each of which exist in multiple isoforms [226] . Activation of AMPK requires phosphorylation of the α subunit and occurs downstream of two kinases; LKB1 and Ca2+/calmodulin-dependent protein kinase kinase β (CaMKKβ) (reviewed elsewhere [226, 227] ). Shear stress-induced AMPK activation in endothelial cells is independent of Akt and involves the activation of the α 2 subunit via LKB1 [226] . AMPK activation can also be mediated pharmacologically with aminoimidazole carboxamide ribonucleotide (AICAR) or metformin. AICAR is a direct activator of AMPK that acts downstream of LKB1 leading to phosphorylation of the α2 subunit of AMPK [226] . In contrast, metformin is an indirect activator of AMPK [228] , actions of which are mediated by an increase in the AMP:ATP ratio resulting from inhibition of Complex I of the respiratory chain [229, 230] . However, such inhibition of oxidative phosphorylation, and a subsequent increase in glycolysis, can have numerous effects independent of AMPK, e.g., metformin effects transcription factors and kinases involved in numerous cell cycle and metabolic pathways (p53, p38, MAPK, PKC and Akt) [231] [232] [233] [234] . Therefore, as with resveratrol, metformin and other non-specific agents are not optimal for mechanistic studies evaluating these pathways but do afford insights as potential therapeutic agents.
AMPK activation in vascular endothelial cells can contribute to both angiogenesis and NO production. Angiogenic effects of AMPK occur both upstream and downstream of vascular endothelial growth factor (VEGF), with the effects of AMPK signaling promoting differentiation of endothelial progenitor cells [235] as well as angiogenesis in isolated myocardial microvascular endothelial cells [236] , in ischemic skeletal muscle [237] and during hypoxia both in vitro and in vivo [238] . AMPK activation also results in increased activation of eNOS [239, 240] via signaling through Rac1 and Akt [238, 240] , as well as through direct phosphorylation of eNOS [241, 242] . While the pro-angiogenic effects of AMPK have been linked to increased VEGF expression [236, 237] , AMPK has also been demonstrated to transcriptionally regulate a number of other proteins involved in inflammation, mitochondrial biogenesis, fatty acid and cholesterol synthesis, glucose metabolism, cell growth and oxidative stress signaling [226] , all of which may impact vascular function. Taken together, these findings suggest that augmenting AMPK signaling may not only enhance angiogenesis and increase bioavailability of NO and vasodilatory responses [235, 238, 240] , but may also impact upstream mediators of age-associated endothelial dysfunction, such as inflammation and oxidative stress. Indeed, AMPK activation improves endothelial function in type I and II diabetic rodents [243] [244] [245] but, less is known about the activation state of AMPK in aged arteries or its role in age-associated vascular dysfunction.
In the context of vascular aging, although there is a report of increased AMPK activation in endothelial cells cultured to senescence, a cellular model of aging [246] , AMPK activity is reduced in the aorta [247] and cerebral arteries [248] of old rodents. Furthermore, the pharmacological activation of AMPK by AICAR increases EDD in old mice [247] , suggesting that inactivation of arterial AMPK contributes to age-associated endothelial dysfunction. However, despite evidence for AMPK-mediated eNOS activation [238, [240] [241] [242] , the effect of in vivo AMPK activation by AICAR to improve dilation in arteries from old mice was not mediated by an increased NO bioavailability [247] . Similar NO independent effects of AICAR were also found after acute in vitro administration to isolated aortic rings, in which AICAR induced relaxation of agonist constricted vessels independent of NO [249] . Similar to treatment of old mice with SIRT-1 activators, AMPK activators therefore reduce arterial oxidative stress and improve endothelial function, but do so in an NO independent mechanism.
5c. Mammalian target of rapamycin (mTOR), Aging and Endothelial Dysfunction
Rapamycin was discovered more than 30 years ago from an Easter Island soil sample. It is a potent antifungal metabolite produced from bacteria and in addition to its antifungal properties was quickly found to have antiproliferative and immunosuppressant properties when used in high quantities. The mammalian target of rapamycin (mTOR) is a signaling protein which responds to nutrients (i.e. amino acids) or growth factors (i.e. insulin) in order to modulate mRNA translation, protein synthesis and cellular growth [250] . mTOR signaling is composed of two distinct pathways the mTOR complex 1 (mTORC1), the more typically studied and rapamycin "sensitive", and mTOR complex 2 (mTORC2), the less clearly identified and less sensitive to rapamycin. Most information to date on the role of mTOR has studied the insulin/nutrient signaling via the mTORC1 and significantly less in known about the role of mTORC2 (in this review, future references measure either mTORC1 or general mTOR activity) [251] . Earlier this decade studies showed that decreasing TOR signaling, genetically or with rapamycin, in yeast, Drosophila, and C. elegans is able to slow aging and increase lifespan [252] [253] [254] [255] . Follow-up studies out of Richard Miller's laboratory reproduced these findings in mice fed a diet with rapamycin incorporated [256, 257] . These studies suggested that inhibiting mTOR via rapamycin could delay age-associated diseases and extend lifespan in mammals. A subsequent study replicated these findings by genetically manipulating a downstream target of mTOR, ribosomal S6 protein kinase (S6K1) and demonstrated a similar phenotype of reduced risk factors for age-related diseases (bone density, insulin sensitivity) and increase lifespan [258] . These studies unilaterally implicate elevated mTOR signaling in accelerated aging and associated diseases. Currently, very little is known about mTOR and endothelial function. We have demonstrated that mTOR signaling is augmented in arteries from older mice which display endothelial dysfunction and lifelong caloric restriction prevents augmented arterial mTOR signaling and endothelial dysfunction [104] . Furthermore, preliminary studies in our lab suggest that 6-8 weeks of dietary supplementation of rapamycin improve NO and endothelial function in old mice [259] . Chronic rapamycin and other rapamycin analog studies are warranted to determine if inhibition of the mTOR pathway is a viable method to improve endothelial function in older adults.
Interactions of mTOR, SIRT1 and AMPK: Role in the Vascular Aging Phenotype
Although the energy sensor pathways, SIRT-1, AMPK activation and mTOR inhibition have been linked to the vascular aging phenotype, when viewed from a wider perspective, what becomes evident is that these pathways do not, in fact, act in parallel to independently impact the macromechanistic processes (e.g. inflammation, oxidative stress and senescence) associated with vascular dysfunction. Rather, there are points of convergence and crosstalk among these pathways that not only impact the downstream effects, but also the expression of the signaling molecules themselves. Indeed, signaling through the transcription factors NFκB, FoxO and p53, represent points of convergence for signaling downstream of mTOR, SIRT-1 and AMPK.
6a. NFκB
The acetylation of NFκB p65 subunit by p300 prevents the nuclear export of NFκB, while its deacetylation by SIRT-1 allows for the association of NFκB with IκB-α and its subsequent nuclear export and inactivation [260] . Inhibition of mTOR (complex 1) by rapamycin inhibits phosphorylation of NFκB and subsequent nuclear translocation via its influence on IKKβ activity [261] [262] [263] . AMPK signaling has a complex interaction with NFκB [264] , such that AMPK can both indirectly inhibit pro-inflammatory NFκB signaling [265] [266] [267] and activate NFκB signaling leading to its anti-apoptotic effects in endothelial cells [268] . Taken together these studies indicate that SIRT-1, mTOR and AMPK can all alter the pro-inflammatory transcription factor NFκB activity by both distinct and intersecting pathways. It also indicates that reductions in AMPK and SIRT-1 activity and conversely increased mTOR activity may increase NFκB signaling resulting in a proinflammatory phenotype similar to that observed in older arteries
6b. FoxO transcription factors
Fox nuclear transcription factors are a family of proteins characterized by a conserved 100 amino-acid sequence known as the "forkhead box." The FoxO subgroup have been implicated in ROS detoxification, cell cycle regulation, apoptosis, and DNA repair [269] . The activity of this subgroup is dependent on posttranslational modifications, such as phosphorylation and acetylation. FoxO proteins are constitutively held in the cytoplasm, and phosphorylation by signaling kinases inhibit their transcriptional activity by preventing nuclear translocation [270] . Phosphorylated FoxO is retained in the cytoplasm by the 14-3-3 chaperone protein, and phosphorylation at serine residues 256/253 [271] targets FoxO proteins for degradation via ubiquitination [272] . The downstream targets of nuclear FoxO activity are determined by acetylation [273] . For example, p300-mediated FoxO3a acetylation induces the preferential transcription of pro-apoptotic gene targets. SIRT-1 deacetylates FoxO3a, leading to the preferential transcription of genes related to stress resistance, such as the antioxidants MnSOD and catalase [273] [274] [275] . Furthermore, the FoxO4 isoform is an endogenous NFκB inhibitor, whose activity is enhanced when bound to SIRT-1 [276] . The interaction of mTOR and FoxO signaling occurs through modulation of other signaling kinases, such as protein kinase B (Akt) and serum-and glucocorticoidregulated kinase-1 (SGK1). The phosphorylation of FoxO proteins by these kinases leads to the cytoplasmic retention and inactivation of FoxO transcription factors [277] . Rapamycin, an inhibitior of mTOR, can inhibit SGK1 activity downstream of the mTORC1 complex [278] and may, as a result, increase FoxO-mediated transcription of anti-oxidant gene targets. AMPK can also directly phosphorylate the 3a isoform of FoxO leading to its activation and subsequent inhibition of NFκB [279] .
6c. p53
p53 is a transcription factor that acts as a tumor suppressor preventing the survival of malignant cells. p53 is activated by stress such as DNA damage, telomere attrition and hypoxia and leads to cell cycle arrest and apoptosis [280] . Endothelial dysfunction in older adults is associated with telomere dysfunction and subsequent increases in p53-mediated cell cycle arrest via increases in the cyclin dependent kinase inhibitor, p21 expression [148] . Furthermore, recent evidence points to a link between the DNA damage response and energy sensitive pathways via SIRT-1 activity and expression. SIRT-1 is involved in the DNA repair and its activity has been shown to protect human and rodent vascular cells from DNA damage in the context of atherosclerosis [281] . Thus, age-related reductions in endothelial SIRT-1 expression and activity [207] may be partly the result of depleted protein levels caused by increased need for repair of accumulating DNA damage. Conversely, reductions in endothelial SIRT-1 expression may lead to genomic instability with advancing age. Specifically SIRT-1 deacetylates p53 resulting in its inactivation and the promotion of cell survival, thus reductions in SIRT-1 activity with aging may contribute to p53 activation and increased cell senescence [282, 283] . Conversely, AMPK phosphorylates p53 on ser15 and ser20 [284, 285] leading to p53 stabilization, activation and cell cycle arrest [286] . Phosphorylation of p53 at these sites has also been associated with reductions in inflammation [284] . Although, AMPK induced decreases in cell senescence does not likely contribute to the aging vascular phenotype, a loss of the p53-associated anti-inflammatory effects of AMPK may be an important factor. The crosstalk between p53 and mTOR occurs in the inverse manner as described for SIRT-1 and AMPK, with p53 inhibiting mTOR activity [287] . However, as both p53 and mTOR activation is increased with vascular aging, it is unlikely that this inhibitory interaction is a significant contributor to the vascular aging phenotype.
Conclusions
Since the initial observations of endothelial dysfunction in older adults in the early 1990s, the field has achieved several significant milestones. First, due to initial work and reviews by early researchers, vascular aging now is appreciated as a critical step in the development of age-related CVD. This recognition has allowed for funding and expansion of the field of study. Second, the vascular aging research community has expanded dramatically in the last 20 years and has established viable primate and rodent models that phenocopy human aging. These models have allowed for greater mechanistic insight into the cellular and molecular mechanisms of endothelial dysfunction as well as the translation of interventions to human endothelial physiology studies. Third, in the past 25 years, the research community has identified multiple pathways that directly influence oxidative stress and inflammation, the major mechanisms of endothelial dysfunction with advancing age. Emerging evidence has suggested several promising pathways that could be viable candidates to reverse age-related endothelial dysfunction that require further exploration in areas outside of endothelial dilation; such as fibrinolysis, permeability and angiogenesis. Unfortunately, it is still unknown what the initiating events are that alter the cellular machinery to induce the well described vicious cycle of oxidative stress and inflammation. Indeed, although deregulation of the energy sensing pathways, e.g., SIRT-1, mTOR and AMPK, are attractive possible mechanisms, to date, pharmacological interventions that restore normal pathway activity in older animals have proven only partially effective at restoring endothelial function to that of young animals. Finally, treating older adults with prescription drugs to improve endothelial function as a preventative measure against CVD is not currently acceptable in the absence of clinical disease. Unless the definition of "clinical disease" is extended to include endothelial dysfunction, the only viable preventative interventions are those involving lifestyle changes or treatments with nutraceuticals. Overall, despite impressive advancements in our understanding of the biology of aging in the endothelium, we as a research community still have fundamental questions to answer including: What are the initiating events that lead to the arterial aging phenotype? And if a target pathway can be identified and viable drugs created to improve endothelial dysfunction in older adults, when should such therapy be initiated?
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